The co-presence of deletion 7q, 20q and inversion 16 in therapy-related acute myeloid leukemia developed secondary to treatment of breast cancer with cyclophosphamide, doxorubicin, and radiotherapy: a case report.

Journal of Medical Case Reports
Ipek YonalMelih Aktan

Abstract

Therapy-related acute myeloid leukemia occurs as a complication of treatment with chemotherapy, radiotherapy, immunosuppressive agents or exposure to environmental carcinogens. We report a case of therapy-related acute myeloid leukemia in a 37-year-old Turkish woman in complete remission from breast cancer. Our patient presented to our facility with fatigue, fever, sore throat, peripheral lymphadenopathy, and moderate hepatosplenomegaly. On peripheral blood and bone marrow aspirate smears, monoblasts were present. Immunophenotypic analysis of the bone marrow showed expression of CD11b, CD13, CD14, CD15, CD33, CD34, CD45 and human leukocyte antigen-DR, findings compatible with the diagnosis of acute monoblastic leukemia (French-American-British classification M5a). Therapy-related acute myeloid leukemia developed three years after adjuvant chemotherapy consisting of an alkylating agent, cyclophosphamide and DNA topoisomerase II inhibitor, doxorubicin and adjuvant radiotherapy. Cytogenetic analysis revealed a 46, XX, deletion 7 (q22q34), deletion 20 (q11.2q13.1) karyotype in five out of 20 metaphases and inversion 16 was detected by fluorescence in situhybridization. There was no response to chemotherapy (cytarabine and idarubici...Continue Reading

References

Apr 1, 1992·Annals of Oncology : Official Journal of the European Society for Medical Oncology·P Chauvel
Jan 1, 1995·Cytogenetics and Cell Genetics·M HöglundF Mitelman
Jan 1, 1995·Cytogenetics and Cell Genetics·M HöglundN Mandahl
Jun 10, 2000·British Journal of Haematology·C H Pui, M V Relling
Jun 18, 2005·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·Claudio PragaDavid Rogers
Aug 1, 2007·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·Debra A PattSharon H Giordano
Jan 18, 2008·Leukemia·J Pedersen-BjergaardD H Christiansen
Mar 27, 2009·Breast Cancer Research and Treatment·Mike G MartinMatthew J Walter
Oct 31, 2009·Chemico-biological Interactions·Maria Teresa VosoGiuseppe Leone
Dec 5, 2009·Chemico-biological Interactions·Zhijian QianMichelle M Le Beau
Dec 23, 2009·Chemico-biological Interactions·Giuseppe LeoneMaria Teresa Voso

❮ Previous
Next ❯

Methods Mentioned

BETA
biopsy
dissection
surgical resection
MDS

Related Concepts

Related Feeds

AML: Role of LSD1 by CRISPR (Keystone)

Find the latest rersearrch on the ability of CRISPR-Cas9 mutagenesis to profile the interactions between lysine-specific histone demethylase 1 (LSD1) and chemical inhibitors in the context of acute myeloid leukemia (AML) here.

Acute Myeloid Leukemia

Acute myeloid leukemia (AML) is a clinically and genetically heterogeneous disease with approximately 20,000 cases per year in the United States. AML also accounts for 15-20% of all childhood acute leukemias, while it is responsible for more than half of the leukemic deaths in these patients. Here is the latest research on this disease.

Related Papers

Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology
L DetourmigniesF Bauters
Haematologica
Nicolaus KrögerMyelodysplastic Syndromes Subcommittee of The Chronic Leukaemia Working Party of European Group for Blood and Marrow Transpl
Zhonghua xue ye xue za zhi = Zhonghua xueyexue zazhi
Long-jun GuLu Dong
© 2022 Meta ULC. All rights reserved